one completely agrees on which of these products best reflects the needed diagnostic and management features of a good blood tumor marker. The full characterization of the antibody's specificity, even if the exact molecule needed to be measured is agreed on, is not a trivial consideration. This point is clearly demonstrated in a recent article on the assessment of serum gastrin concentration, which is a widely used radioimmunoassay in medicine. Numerous NH 2 and COOH terminal extended gastrins circulate that are sulfated and nonsulfated. Whereas there is general agreement that assessment of the biologically active amidated COOH terminus is clinically important, a recent study demonstrates 11 that 7 of 12 commercially available assays do not accurately measure the clinically important gastrin because they are using not fully characterized antibodies. Therefore, even if agreement is reached on the CgA molecule to be measured, good characterization and standardization are needed.
There is disagreement in the literature whether blood CgA levels correlate with the extent of tumor or growth of the tumor and are useful for the management of NETs. 5, 6, 12, 13 Furthermore, blood CgA levels are frequently decreased by the use of somatostatin analogs that are commonly used in the treatment of functional and nonfunctional NETs either alone or in combination with other drugs, and it is unclear whether their effect is variable, making it difficult to perform assessments when these commonly used drugs are administered. Assessment of CgA levels has also failed as a tumor marker for the early detection of NETs. This has primarily occurred because CgA levels are affected not only by the NET, but numerous other processes including inflammatory disorders, other endocrine diseases, gastrointestinal disorders, cardiovascular diseases, renal function, and, particularly important, the use of potent acid suppressant drugs such as proton pump inhibitors (PPIs). 6, 14 The PPIs are a particular problem because they increase blood CgA in 90% to 100% of patients with protracted use; they are widely used and available now over the counter so their use is often not even mentioned in the medical history; they increase blood CgA after only 5 days of use and they can lead to CgA levels 5-to 10-fold normal, which overlap with that seen in many patients with early NETs. 15 It is in this latter context that the study by Raines et al, 4 reporting results of a recently described specific radioimmunoassay for pancreastatin 12 in patients taking PPIs, is of particular interest. Human pancreastatin is a 52Yamino acid peptide corresponding to CgA (250Y301) 9 ( Fig. 1) , and its generation from CgA depends to a large part on the activity of prohormone convertase-1. 16 Pancreastatin is present in NETs, 17, 18 is present in picomolar concentrations in normal plasma 12, 19 primarily as the CgA (250Y301) form and in higher molecular weight forms. 19 The results of the study by Raines et al 4 are particularly important because they show no increase in plasma pancreastatin levels in patients chronically taking PPIs, whereas serum gastrin is increased in all and CgA levels in almost 70%. 4 These results are of particular interest because they raise the possibility that plasma pancreastatin could be a more sensitive and specific assay than CgA in detecting early NETs as well as nonfunctional NETs and possibly useful for management. Is there any evidence to support these speculations? The principal finding of this study is supported by results of an early study by Syversen et al 20 using a specific pancreastatin assay in patients with gastrinomas, where they found plasma pancreastatin levels to correlate closely with gastrin levels, but not with CgA levels, leading them to propose the there is little or no processing of CgA to pancreastatin in ECL cells; whereas in gastrinoma cells, it is extensive. Will this assay be sensitive enough to be useful? That remains to be proven. In one study 20 using a different antibody from that used in the study by Raines et al, 4 plasma pancreastatin levels were normal in 44% of patients with gastrinomas 20 and in another study in 27% of patients with NETs and 100% of patients with NETs with only lymph node metastases. 21 Will it be specific enough for NETs? At present, this is also not proven.
Hopefully, lessons will be learned from the experience with CgA, and these questions will be answered rapidly. Particularly important will be, in all assays for plasma pancreastatin, the complete characterization of all antibodies generated for crossreactivity with the various CgA products that could react within the assay (Fig. 1) . Next, the inclusion of patients with a wide variety of conditions that lead to false-positives, as seen in the 
